A Phase 3 Study to Determine if RTB101 Prevents Clinically Symptomatic Respiratory Illness in the Elderly
Status:
Completed
Trial end date:
2019-12-02
Target enrollment:
Participant gender:
Summary
To determine if RTB101 as compared to placebo decreases the percentage of subjects with
clinically symptomatic respiratory illness (with or without an associated
laboratory-confirmed pathogen) through Week 16.